The U.S. Food and Drug Administration has given approval for naloxone, the overdose-reversing drug, to be sold without a prescription. This decision will make it the first opioid treatment drug that can be purchased over the counter. Advocates believe that making naloxone available more widely is a key strategy to tackle the overdose crisis, which has been linked to more than 100,000 U.S. deaths a year. The FDA’s decision permits the branded nasal spray version of naloxone by Emergent BioSolutions to be sold without a prescription, and it is expected to become available over the counter by late summer. However, it is unclear how many stores will carry it and whether insurers will continue to cover it. Ultimately, it remains to be seen how many people will purchase it and be able to use it properly.